Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $43.71.

Several analysts have recently weighed in on ARWR shares. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday. Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Finally, B. Riley restated a “buy” rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th.

Arrowhead Pharmaceuticals Stock Down 1.4%

ARWR stock opened at $16.57 on Tuesday. The firm’s 50-day moving average is $13.80 and its two-hundred day moving average is $17.32. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -3.21 and a beta of 0.96. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $30.41. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same period in the previous year, the firm earned ($1.02) EPS. On average, analysts forecast that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 40,322 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $10.07, for a total value of $406,042.54. Following the completion of the sale, the chief executive officer now directly owns 4,022,055 shares of the company’s stock, valued at $40,502,093.85. The trade was a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 142,547 shares of company stock worth $1,764,709 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Xponance Inc. raised its position in shares of Arrowhead Pharmaceuticals by 4.5% in the fourth quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company’s stock valued at $327,000 after purchasing an additional 744 shares during the period. Summit Investment Advisors Inc. grew its stake in Arrowhead Pharmaceuticals by 2.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock valued at $714,000 after buying an additional 803 shares during the last quarter. Oak Ridge Investments LLC raised its holdings in Arrowhead Pharmaceuticals by 2.5% in the 1st quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company’s stock worth $430,000 after acquiring an additional 823 shares during the period. Empowered Funds LLC lifted its position in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 979 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 10.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 1,195 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.